Devi Parthiban Brindha, Jogula Sridhar, Reddy Asireddy Parameshwar, Saxena Shalini, Sridevi Jonnalagadda Padma, Sriram Dharmarajan, Yogeeswari Perumal
Centre for Infectious Diseases Research, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad-500078, India phone: +9140-66303515; fax: +9140-66303998.
Mol Inform. 2015 Feb;34(2-3):147-59. doi: 10.1002/minf.201400120. Epub 2015 Feb 17.
Pantothenate synthetase (PS) enzyme involved in the pantothenate biosynthetic pathway is essential for the virulence and persistent growth of Mycobacterium tuberculosis (MTB). It is encoded by the panC gene, and has become an appropriate target for developing new therapeutics for tuberculosis. Here we report new inhibitors active against MTB PS developed using energy based pharmacophore modelling of the available proteininhibitor complex (3IVX) and virtual screening of a large commercial library. The e-pharmacophore model consisted of a ring aromatic (R), negative ionizable (N) and acceptor (A) sites. Compounds 5 and 10 emerged as promising hits with IC50 s 2.18 µM and 6.63 µM respectively. Further structural optimization was attempted to optimize lead 10 using medicinal chemistry approach and six compounds were found to exhibit better enzyme inhibition compared to parent compound lead 10 (<6 µM).
泛酸合成酶(PS)参与泛酸生物合成途径,对结核分枝杆菌(MTB)的毒力和持续生长至关重要。它由panC基因编码,已成为开发新型结核病治疗药物的合适靶点。在此,我们报告了通过基于能量的药效团模型对可用的蛋白质-抑制剂复合物(3IVX)进行建模以及对大型商业文库进行虚拟筛选而开发出的对MTB PS具有活性的新型抑制剂。电子药效团模型由一个环状芳香族(R)、可电离负离子(N)和受体(A)位点组成。化合物5和10成为有前景的命中物,其IC50分别为2.18 μM和6.63 μM。尝试使用药物化学方法对先导化合物10进行进一步的结构优化,发现有六种化合物与母体化合物先导化合物10相比表现出更好的酶抑制作用(<6 μM)。